Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924793 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
A Phase 2 study, sponsored by Ansun Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01924793: Completed Phase 2 study, sponsored by Ansun Biopharma.
NCT01924793 is a Phase 2 study that has completed, run by Ansun Biopharma. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924793, a Phase 2 study, has completed, sponsored by Ansun Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
Interventions
- DRUG DAS181-F02 Dry Powder in Bulk
- DRUG DAS181-F02 Nebulized Formulation Inhaled Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
What the finished NCT01924793 record still lists
NCT01924793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which DAS181-F02 Dry Powder in Bulk is the first listed.
NCT01924793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01924793 about?
NCT01924793 is a clinical study titled "An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection". This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
What is the current status of trial NCT01924793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2013-08. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01924793?
The interventions under investigation include: DAS181-F02 Dry Powder in Bulk (DRUG), DAS181-F02 Nebulized Formulation Inhaled Dose (DRUG).
Who is sponsoring clinical trial NCT01924793?
This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01924793's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia